Charm Therapeutics closed an $80 million Series B financing round aimed at advancing its next-generation menin inhibitor into clinical development. Menin inhibitors show promise in acute myeloid leukemia (AML) treatment but are limited by resistance mutations. Charm’s lead candidate is designed to overcome these barriers, potentially improving durability of responses. The funding will support IND-enabling studies and initial clinical trials, representing a significant investment in innovative targeted therapies for AML.